246 related articles for article (PubMed ID: 33037990)
21. Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR.
Chng WJ; Goldschmidt H; Dimopoulos MA; Moreau P; Joshua D; Palumbo A; Facon T; Ludwig H; Pour L; Niesvizky R; Oriol A; Rosiñol L; Suvorov A; Gaidano G; Pika T; Weisel K; Goranova-Marinova V; Gillenwater HH; Mohamed N; Feng S; Aggarwal S; Hájek R
Leukemia; 2017 Jun; 31(6):1368-1374. PubMed ID: 28025582
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study.
Muchtar E; Gatt ME; Rouvio O; Ganzel C; Chubar E; Suriu C; Tadmor T; Shevetz O; Lavi N; Shochat T; Cohen YC; Avivi I; Raanani P; Magen H
Br J Haematol; 2016 Jan; 172(1):89-96. PubMed ID: 26567759
[TBL] [Abstract][Full Text] [Related]
23. A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma.
Watanabe T; Tobinai K; Matsumoto M; Suzuki K; Sunami K; Ishida T; Ando K; Chou T; Ozaki S; Taniwaki M; Uike N; Shibayama H; Hatake K; Izutsu K; Ishikawa T; Shumiya Y; Kashihara T; Iida S
Br J Haematol; 2016 Mar; 172(5):745-56. PubMed ID: 26732066
[TBL] [Abstract][Full Text] [Related]
24. Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study.
Goldschmidt H; Moreau P; Ludwig H; Niesvizky R; Chng WJ; Joshua D; Weisel K; Spencer A; Orlowski RZ; Feng S; Iskander KS; Dimopoulos MA
Leuk Lymphoma; 2018 Jun; 59(6):1364-1374. PubMed ID: 28937327
[TBL] [Abstract][Full Text] [Related]
25. An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma.
Jagannath S; Vij R; Stewart AK; Trudel S; Jakubowiak AJ; Reiman T; Somlo G; Bahlis N; Lonial S; Kunkel LA; Wong A; Orlowski RZ; Siegel DS
Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):310-8. PubMed ID: 23040437
[TBL] [Abstract][Full Text] [Related]
26. A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma.
Alsina M; Trudel S; Furman RR; Rosen PJ; O'Connor OA; Comenzo RL; Wong A; Kunkel LA; Molineaux CJ; Goy A
Clin Cancer Res; 2012 Sep; 18(17):4830-40. PubMed ID: 22761464
[TBL] [Abstract][Full Text] [Related]
27. Carfilzomib monotherapy in Japanese patients with relapsed or refractory multiple myeloma: A phase 1/2 study.
Iida S; Watanabe T; Matsumoto M; Suzuki K; Sunami K; Ishida T; Ando K; Chou T; Ozaki S; Taniwaki M; Uike N; Shibayama H; Hatake K; Izutsu K; Ishikawa T; Shumiya Y; Tobinai K
Cancer Sci; 2019 Sep; 110(9):2924-2932. PubMed ID: 31336012
[TBL] [Abstract][Full Text] [Related]
28. Carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience of Rete Ematologica Pugliese (REP).
Mele A; Prete E; De Risi C; Citiso S; Greco G; Falcone AP; Sanpaolo G; Mele G; Giannotta A; Vergine C; Reddiconto G; Palazzo G; Sabatelli S; Germano C; Miccolis R; Curci P; Palumbo G; Offidani M; Rizzi R; Cascavilla N; Pastore D; Di Renzo N; Mazza P; Tarantini G; Guarini A; Capalbo S; Specchia G; Greco A; De Francesco R; Sibilla S; Tonialini L; Morciano MR; Pavone V
Ann Hematol; 2021 Feb; 100(2):429-436. PubMed ID: 33161453
[TBL] [Abstract][Full Text] [Related]
29. Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma.
Chari A; Cornell RF; Gasparetto C; Karanes C; Matous JV; Niesvizky R; Lunning M; Usmani SZ; Anderson LD; Chhabra S; Girnius S; Shustik C; Stuart R; Lee Y; Salman Z; Liu E; Valent J
Hematol Oncol; 2020 Aug; 38(3):353-362. PubMed ID: 32053229
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes.
Hari P; Mateos MV; Abonour R; Knop S; Bensinger W; Ludwig H; Song K; Hajek R; Moreau P; Siegel DS; Feng S; Obreja M; Aggarwal SK; Iskander K; Goldschmidt H
Leukemia; 2017 Dec; 31(12):2630-2641. PubMed ID: 28439109
[TBL] [Abstract][Full Text] [Related]
31. Weekly carfilzomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma: A phase 1 and PK/PD trial.
Maruyama D; Tobinai K; Chou T; Taniwaki M; Shumiya Y; Iida S
Cancer Sci; 2018 Oct; 109(10):3245-3252. PubMed ID: 30058108
[TBL] [Abstract][Full Text] [Related]
32. A practical review on carfilzomib in multiple myeloma.
Muchtar E; Gertz MA; Magen H
Eur J Haematol; 2016 Jun; 96(6):564-77. PubMed ID: 26893241
[TBL] [Abstract][Full Text] [Related]
33. Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study.
Biran N; Siegel D; Berdeja JG; Raje N; Cornell RF; Alsina M; Kovacsovics T; Fang B; Kimball AS; Landgren O
Am J Hematol; 2019 Jul; 94(7):794-802. PubMed ID: 31021005
[TBL] [Abstract][Full Text] [Related]
34. Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
Korde N; Roschewski M; Zingone A; Kwok M; Manasanch EE; Bhutani M; Tageja N; Kazandjian D; Mailankody S; Wu P; Morrison C; Costello R; Zhang Y; Burton D; Mulquin M; Zuchlinski D; Lamping L; Carpenter A; Wall Y; Carter G; Cunningham SC; Gounden V; Sissung TM; Peer C; Maric I; Calvo KR; Braylan R; Yuan C; Stetler-Stevenson M; Arthur DC; Kong KA; Weng L; Faham M; Lindenberg L; Kurdziel K; Choyke P; Steinberg SM; Figg W; Landgren O
JAMA Oncol; 2015 Sep; 1(6):746-54. PubMed ID: 26181891
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma.
Facon T; Niesvizky R; Mateos MV; Siegel D; Rosenbaum C; Bringhen S; Weisel K; Ho PJ; Ludwig H; Kumar S; Wang K; Obreja M; Yang Z; Klippel Z; Mezzi K; Goldrick A; Tekle C; Dimopoulos MA
Blood Adv; 2020 Nov; 4(21):5449-5459. PubMed ID: 33166401
[TBL] [Abstract][Full Text] [Related]
36. A phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.
Alsina M; Landgren O; Raje N; Niesvizky R; Bensinger WI; Berdeja JG; Kovacsovics T; Vesole DH; Fang B; Kimball AS; Siegel DS
Am J Hematol; 2021 Feb; 96(2):226-233. PubMed ID: 33125764
[TBL] [Abstract][Full Text] [Related]
37. The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy.
Tzogani K; Camarero Jiménez J; Garcia I; Sancho-López A; Martin M; Moreau A; Demolis P; Salmonson T; Bergh J; Laane E; Ludwig H; Gisselbrecht C; Pignatti F
Oncologist; 2017 Nov; 22(11):1339-1346. PubMed ID: 28935772
[TBL] [Abstract][Full Text] [Related]
38. Evolution of carfilzomib dose and schedule in patients with multiple myeloma: a historical overview.
Jakubowiak AJ
Cancer Treat Rev; 2014 Jul; 40(6):781-90. PubMed ID: 24630735
[TBL] [Abstract][Full Text] [Related]
39. A phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma: Final analysis of second dose-expansion cohort.
Berdeja JG; Gregory TK; Faber EA; Hart LL; Mace JR; Arrowsmith ER; Flinn IW; Matous JV
Am J Hematol; 2021 Apr; 96(4):428-435. PubMed ID: 33421178
[TBL] [Abstract][Full Text] [Related]
40. Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma.
Berdeja JG; Hart LL; Mace JR; Arrowsmith ER; Essell JH; Owera RS; Hainsworth JD; Flinn IW
Haematologica; 2015 May; 100(5):670-6. PubMed ID: 25710456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
